- Home
- AVTX vs RCEL Comparison
AVTX vs RCEL Comparison
Compare AVTX & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- RCEL
- Stock Information
- Founded
- AVTX 2011
- RCEL N/A
- Country
- AVTX United States
- RCEL United States
- Employees
- AVTX N/A
- RCEL N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- AVTX Health Care
- RCEL Health Care
- Exchange
- AVTX Nasdaq
- RCEL Nasdaq
- Market Cap
- AVTX 138.8M
- RCEL 113.7M
- IPO Year
- AVTX 2015
- RCEL N/A
- Fundamental
- Price
- AVTX $10.66
- RCEL $4.55
- Analyst Decision
- AVTX Strong Buy
- RCEL Strong Buy
- Analyst Count
- AVTX 8
- RCEL 4
- Target Price
- AVTX $31.00
- RCEL $13.75
- AVG Volume (30 Days)
- AVTX 209.8K
- RCEL 284.9K
- Earning Date
- AVTX 11-06-2025
- RCEL 11-06-2025
- Dividend Yield
- AVTX N/A
- RCEL N/A
- EPS Growth
- AVTX N/A
- RCEL N/A
- EPS
- AVTX N/A
- RCEL N/A
- Revenue
- AVTX $441,000.00
- RCEL $74,884,000.00
- Revenue This Year
- AVTX N/A
- RCEL $28.23
- Revenue Next Year
- AVTX N/A
- RCEL $35.24
- P/E Ratio
- AVTX N/A
- RCEL N/A
- Revenue Growth
- AVTX N/A
- RCEL 38.32
- 52 Week Low
- AVTX $3.39
- RCEL $3.60
- 52 Week High
- AVTX $16.00
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- AVTX 61.15
- RCEL 46.31
- Support Level
- AVTX $8.65
- RCEL $4.12
- Resistance Level
- AVTX $12.41
- RCEL $4.44
- Average True Range (ATR)
- AVTX 0.88
- RCEL 0.25
- MACD
- AVTX -0.00
- RCEL 0.03
- Stochastic Oscillator
- AVTX 54.79
- RCEL 48.86
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.